Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic LeukemiaMatthew S. Davids, Jennifer R. Brown, Chinheng Chen et al.|Blood|2021Cited by 4